# Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

> **NCT06156761** · NA · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 24 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Mitoxantrone hydrochloride liposome
- **DRUG:** Capecitabine
- **DRUG:** Mitoxantrone hydrochloride liposome
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06156761
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-28
- **Primary completion:** 2024-04
- **Final completion:** 2025-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06156761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06156761, "Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06156761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*